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Angiopoietin-1 (Ang1) is an essential molecule for
blood vessel formation; however, little is known about
the structure-function relationships of Ang1 with its re-
ceptor, Tie2 (tyrosine kinase with immunoglobulin and
epidermal growth factor homology domain-2). In this
study, we generated several Ang1 and angiopoietin-2
(Ang2) variants to define the role of the superclustering
and oligomerization domains of the Ang1 protein. Then
we analyzed the molecular structure of the variants
with SDS-PAGE and rotary metal-shadowing transmis-
sion electron microscopy (RMSTEM) and determined
the effects of these variants on the binding and activa-
tion of Tie2. Ang1 exists as heterogeneous multimers
with basic trimeric, tetrameric, and pentameric oli-
gomers, whereas Ang2 exists as trimeric, tetrameric,
and pentameric oligomers. The variant Ang1C265S, con-
sisting of trimers, tetramers, and pentamers without
multimeric forms of Ang1, yielded less Tie2 activation
than did Ang1, whereas monomeric Ang1 (Ang1/FD), di-
meric Ang1 variants (Ang1D2, and Ang1D3), and dimeric
and trimeric Ang1 variant (Ang1D1) dramatically lost
their ability to bind and activate Tie2. An Ang1 protein
in which two cysteines (amino acids 41 and 54) were
replaced with serines (Ang1C41S/C54S) formed mostly
dimers and trimers that were not able to bind and acti-
vate Tie2. In addition, improper creation of a new cys-
teine in Ang2 (Ang2S263C) dramatically induced Ang2
aggregation without activating Tie2. In conclusion,
proper oligomerization of Ang1 having at least four sub-
units by the intermolecular disulfide linkage involving
cysteines 41 and 54 is critical for Tie2 binding and acti-
vation. Thus, our data shed a light on the structure-
function relationships of Ang1 with Tie2.
Angiopoietin-1 (Ang1)1 was discovered as a secreted protein
ligand of tyrosine kinase with immunoglobulin and epidermal
growth factor homology domain-2 (Tie2) (1). Tie2 is a member
of the receptor tyrosine kinase family and is expressed predom-
inantly on vascular endothelial cells and early hematopoietic
cells (2–4). Ang1- and Tie2-deficient mice have similar pheno-
types characterized by embryonic lethality with severe defects
in vascular remodeling, insufficient vessel stabilization, and
perturbed vascular maturation, indicating that Ang1 and Tie2
play critical roles in vascular development (5, 6). Accordingly,
transgenic overexpression or gene transfer of Ang1 not only
enhances vessel formation, but also protects the adult vascu-
lature against vascular leakage (7–10). In addition, Ang1 can
counteract vascular endothelial growth factor-induced side ef-
fects (9, 11) while having an additive effect on vessel formation
(8, 10). Thus, Ang1 is a very promising growth factor for ther-
apeutic angiogenesis (12, 13). Moreover, in a series of experi-
ments, we found that the Ang1/Tie2 system in normal adult
blood vessels was important in maintaining the integrity of
nonproliferating endothelial cells by strongly inducing endo-
thelial cell survival against insult-mediated damage (14–16).
Furthermore, recent series of reports (11, 17–20) indicate that
Ang1 has anti-inflammatory actions in the cardiovascular sys-
tem. All of these beneficial effects of Ang1 are exerted through
activation of Tie2.
The Ang1 structure consists of a carboxyl-terminal fibrino-
gen-like domain that is responsible for receptor binding, a
central coiled-coil domain that may be responsible for oligomer-
izing these fibrinogen-like domains, and a short amino-termi-
nal domain that superclusters these oligomers into variably
sized multimers (1, 14, 15). Because of this unique structure of
Ang1, production of recombinant Ang1 is hindered by aggrega-
tion and insolubility of the protein. The activity of the protein
frequently varies after purification. To achieve Tie2 receptor
oligomerization and activation, Ang1 uses an oligomeric and
multimeric structure unlike that of any other known growth
factor (14–16). Through low stringency hybridization screening
with Ang1, angiopoietin-2 (Ang2) was identified (17). Ang1 and
Ang2 share a similar structure, with about 60% amino acid
identity, and both have a similar affinity to Tie2 (1, 17). Ang2
was originally thought to be a naturally occurring antagonist of
Ang1 which competes in binding to Tie2 and blocks Ang1-
induced Tie2 autophosphorylation (17). However, recent data
suggest that Ang2 seems to have context-specific effects, acti-
vating Tie2 on some cells while blocking Tie2 activation on
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other cells or under different conditions with unknown reasons
(18–20).
Detailed structural information on a protein ligand is indis-
pensable to understand how it activates its receptor. However,
remarkably little is known about the structure-function rela-
tionships of Ang1 with Tie2. Therefore, in this study, we char-
acterized native Ang1 and Ang2 proteins derived from cultured
cells and generated several recombinant Ang1 and Ang2 vari-
ants to define the role of the superclustering and oligomeriza-
tion domains of Ang1. Then we analyzed the molecular struc-
ture of the variants with SDS-PAGE and rotary metal-
shadowing transmission electron microscopy (RMSTEM), and
determined the effects of Ang1 and Ang2 variants on binding
and activation of Tie2. Our results reveal that two cysteines in
the amino-terminal portion of Ang1 are critical for binding and
activation of Tie2.
EXPERIMENTAL PROCEDURES
Gene Constructs—The pcDNA vector (Invitrogen) contains a secre-
tory signal sequence for hemagglutinin and a FLAG tag. This vector
was used to express all proteins in this study. These proteins were:
full-length human Ang1 (Ang1), Ang1/FD (amino acids 256–498), trun-
cated proteins Ang1D1 (amino acids 81–498), Ang1D2 (amino acids
119–498), Ang1D3 (amino acids 153–498), replacement of cysteine at
265 in Ang1 with serine (Ang1C265S), replacement of cysteine at 41
and 54 with serine in Ang1 (Ang1C265S), the full sequence of human
Ang2 (Ang2), and replacement of serine at 263 with cysteine in Ang2
(Ang2S263C). All recombinant plasmids were constructed using stand-
ard molecular cloning methods. For substitution of amino acids in the
vector, a site-directed mutagenesis kit was used, following the manu-
facturer’s instructions (Stratagene).
Transfection and Purification of the Recombinant Proteins—The re-
combinant proteins were obtained by transient expression in human
embryonic kidney 293 (HEK293) cells (American Type Culture Collection)
using Effectene liposomal transfection according to the manufacturer’s
instructions (Qiagen, Inc.). HEK293 cells were maintained with Dulbec-
co’s modified Eagle’s medium supplemented with 20% (v/v) heat-inacti-
vated fetal bovine serum at 37 °C in 5%CO2. Transfection efficiency of the
genes was 60–70%. The supernatant was harvested from transfected
cells after 48–96 h. The recombinant proteins containing the FLAG se-
quence were purified by column chromatography on anti-FLAG M1 anti-
body agarose affinity gel (Sigma). After purification of HEK293 superna-
tants, recombinant proteins were quantitated using the Bradford assay
and confirmed with Coomassie Blue staining of an SDS-polyacrylamide
gel. These analyses showed that the yield was 200–250 g of each recom-
binant protein/liter of HEK293 cell supernatant.
Characterization of the Recombinant Proteins—SDS-PAGE analyses
of proteins were performed under nonreducing and reducing (heating
for 10 min in 0.435 M -mercaptoethanol) conditions. Binding of the
recombinant proteins to the soluble extracellular domain of Tie1-Fc
(sTie1-Fc, T1) or Tie2-Fc (sTie2-Fc, T2) (R&D Systems) was assayed
using an in vitro binding assay. Each recombinant protein (20 ng) was
mixed with 100 ng of sTie1-Fc or sTie2-Fc and incubated in 500 l of
Tris buffer solution (50 mM Tris, 100 mM NaCl, pH 7.4) containing
0.02% Triton X-100 at 4 °C for 2 h. Then, 20 l of protein A-agarose
beads (Oncogene, San Diego) was added and incubated for another 1 h
at 4 °C. The protein A-conjugated samples were washed twice with 1 ml
of Tris buffer containing 0.02% Triton X-100. The samples were eluted
with sample buffer and heat denatured. The samples were separated
further by gradient SDS-PAGE, stained with Coomassie Blue, or elec-
troblotted onto nitrocellulose membranes and probed with anti-FLAG
M1 antibody.
Characterization of the Native Ang1 and Ang2 Proteins—To obtain
secreted native Ang1 and Ang2, we collected culture medium from
undifferentiated 3T3-L1 cells (21) and human umbilical vein endothe-
lial cells (HUVECs) (22). The 3T3-L1 cells were obtained from the
American Type Culture Collection and maintained in Dulbecco’s mod-
ified Eagle’s medium supplemented with 10% heat-inactivated serum.
HUVECs were prepared from human umbilical cords by collagenase
digestion and maintained as described previously (23). The primary
cultured HUVECs used for this study were between passages 2 and 3.
Culture medium (100 ml) that had been on undifferentiated 3T3-L1
cells or HUVECs for 72 h was incubated with 2 g of sTie2-Fc for 2 h at
4 °C. Ang1sTie2-Fc or Ang2sTie2-Fc complexes were recovered on
protein A/G-agarose beads (Calbiochem). The beads were washed three
times with ice-cold radioimmune precipitation assay buffer (1% Triton
X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, and 0.01 M
Tris, pH 7.4), dissolved in sample buffer, boiled, separated by SDS-
PAGE, and Western blotted with anti-Ang1 antibody (PA-hAng1FD-1)
(16) or anti-Ang2 antibody (R&D Systems).
Glycerol Spraying/Low Angle Rotary Metal Shadowing and TEM—
For glycerol spraying/low angle rotary metal shadowing, 20 l of pro-
tein samples, 0.02–0.1 mg/ml in TBS, plus 30% glycerol, were sprayed
onto freshly cleaved mica at room temperature and rotary shadowed in
a BA 511 M freeze-etch apparatus (Balzers) with platinum/carbon at an
elevation angle of 3–5° (24). Electron micrographs were taken in a
Philips Morgagni TEM operated at 80 kV equipped with a Megaview III
CCD camera.
Tie2 Phosphorylation Assays—Tie2 phosphorylation assays using
HUVECs were performed as described previously (15, 23). All signals
from immunoblotting were visualized and analyzed by densitometric
scanning (LAS-1000, Fuji Film, Tokyo).
Statistics—Data are expressed as the mean  S.D. Statistical signif-
icance was tested using one-way analysis of variance followed by the
Student-Newman-Keuls test. Statistical significance was set at
p  0.05.
RESULTS
Comparison of Oligomerization andMultimerization between
Ang1 and Ang2—The domain structures of Ang1 and Ang2 are
shown in Fig. 1A. SDS-PAGE analysis of the purified native
Ang1 protein from undifferentiated 3T3-L1 cells and Ang2
protein from HUVECs under denaturing reduced conditions
exhibited predominant single bands of the expected molecular
masses,70 and62 to70 kDa (Fig. 1B). Under nonreducing
conditions, the native Ang1 protein formed large variable mul-
timers, whereas native Ang2 protein mainly formed disulfide-
linked dimers. Similar to native Ang1 and Ang2, SDS-PAGE
analysis of the purified recombinant Ang1 and Ang2 proteins
under denaturing reduced conditions exhibited predominant
single bands of the expected molecular masses, 70 and 62
kDa (Fig. 1C). Under nonreducing conditions, the recombinant
Ang1 protein formed large variable multimers, whereas recom-
binant Ang2 protein mainly formed disulfide-linked dimers
(Fig. 1C). To confirm the oligomeric structure of recombinant
Ang1 and Ang2 proteins, we used RMSTEM to image the
molecules directly. Approximately 45–50% of the images ob-
tained from Ang1 protein showed the molecules in trimeric,
tetrameric, and pentameric states with mushroom-shaped
structures, consisting of an irregular bulbous “cap” structure
(fibrinogen-like domain, globular domain) at the end of a
“stalk” structure (coiled-coil domain, rod domain) with a small
globular structure (superclustering domain, small globular do-
main) at the other end of the stalk (Fig. 1C). The remaining
50–55% of the images obtained from Ang1 protein showed
variations on the basic coiled-coil building block, with the tri-
mers, tetramers, and pentamers coming together by amino-
terminal clustering at a central point (Fig. 1C). These data
indicate that recombinant Ang1 protein is heterogeneous with
respect to the degree of multimerization, assuming basic tri-
mer, tetramer, and pentameric groupings. In comparison,
80–90% of the images obtained from Ang2 protein showed
molecules in trimeric, tetrameric, and pentameric states yield-
ing mushroom-shaped structures like those seen with Ang1.
Approximately 10–20% of the images obtained from Ang2 pro-
tein showed variations on the basic coiled-coil building block,
with the trimers, tetramers, and pentamers coming together by
amino-terminal clustering at a central point.
Demultimerization of Ang1 Has a Moderate Effect on Tie2
Phosphorylation, whereas Ang2 Aggregates Have Little Effect
on Tie2 Phosphorylation—The difference in multimerization
status between Ang1 and Ang2 could result from the presence
or absence of a cysteine residue in the linker region (Fig. 1A).
To clarify the role of this cysteine residue in the linker region of
Ang1 and Ang2, we generated recombinant proteins replacing
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cysteine 265 with serine in Ang1 (Ang1C265S) and replacing
serine 263 with cysteine in Ang2 (Ang2S263C) (Fig. 2). SDS-
PAGE analysis of the purified Ang1C265S proteins under non-
reducing conditions gave rise to a main fraction of a single band
of an unexpected molecular mass (120 kDa) and a small
fraction of high order oligomers that may have resulted from
disulfide bond between cysteine 41 and cysteine 54. In compar-
ison, Ang2S263C formed large variably sized multimers (Fig.
3A). RMSTEM analysis revealed that Ang1C265S formed
mainly trimers, tetramers, and pentamers without high order
multimers, whereas Ang2S263C showed many nonspecific ag-
gregates with rare cases of trimers, tetramers, and pentamers
(Fig. 3B). Ang1C265S-induced Tie2 phosphorylation activity
was moderately less than Ang1-induced Tie2 phosphorylation
activity in HUVECs (Fig. 3C). In comparison, no notable dif-
ference was detected in Tie2 phosphorylation induced by Ang2
and Ang2S263C. Therefore, naturally, cysteine 265-induced
Ang1 multimerization could be required for its full activity in
Tie2 phosphorylation. In comparison, additional formation of
disulfide bridges through additional insertion of cysteine in the
linker region of Ang2 generated nonspecific aggregates rather
than natural high ordered multimeric Ang2.
Proper Oligomerization/Multimerization of Ang1 by the Su-
perclustering Domain Is a Prerequisite for Tie2 Binding and
Activation—To examine the role of the superclustering domain
and the coiled-coil oligomerization domain of Ang1 in its amino-
terminal portion, we generated a truncated protein, Ang1/FD,
which only has the linker domain and the fibrinogen-like do-
main of Ang1 (Fig. 2). Recombinant Ang1/FD protein formed a
monomer with an apparent molecular mass of 34 kDa (Fig.
4A). In marked contrast to native Ang1, Ang1/FD did not bind
to Tie2 (Fig. 4B) nor phosphorylate Tie2 (Fig. 4C). These find-
ings suggested that oligomerization/multimerization of Ang1
by its amino-terminal region is a prerequisite for Tie2 binding
and activation. To define the role of the amino-terminal portion
of Ang1, serially truncated recombinant Ang1 proteins,
Ang1D1, Ang1D2, and Ang1D3, were made (Fig. 2). SDS-PAGE
analysis of the purified proteins under denaturing conditions
revealed predominantly single bands of the expected molecular
masses (Fig. 5A). Under nonreducing conditions, Ang1D1,
Ang1D2, and Ang1D3 formed characteristic disulfide-linked
dimers (Fig. 5A). To confirm the oligomeric structure of these
three proteins, we used RMSTEM to image the molecules di-
rectly. Approximately 85–90% of the images obtained from
Ang1D1 showed dimers and trimers with a rod domain that
was barely visible (Fig. 5B). In comparison, approximately,
90–95% of the images obtained from Ang1D2 and Ang1D3
showed dimers without a visible rod domain (Fig. 5B). In vitro
binding assays revealed that 72, 12, 4, and 6% of the total
amount of native Ang1, Ang1D1, AngD2, and Ang1D3, respec-
tively, bound to sTie2-Fc (Fig. 5C). None of them bound to
FIG. 1. Protein structure analyses of native Ang1 and Ang2. A,
schematic diagram of the protein structure of Ang1 and Ang2. Amino
acids 1–19 and 1–18 are the secretory signal sequences (S), amino acids
20–79 and 19–70 are the superclustering domain (SCD), amino acids
80–263 and 71–258 are the coiled-coil oligomerization domain (CCOD),
amino acids 264–283 and 257–281 are the linker region (L), and amino
acids 284–498 of Ang1 and 282–496 are the fibrinogen-like domain
(FLD) of Ang1 and Ang2, respectively. Ang1 contains cysteines (C) at
positions 41, 54, 265, 286, 315, 435, 437, 439, and 452, and Ang2
contains cysteines at amino acids 41, 54, 284, 313, 433, 435, 437, and
450. B, nonreduced (NR) and reduced (R) native Ang1 protein from
undifferentiated 3T3-L1 cells and Ang2 protein from HUVECs were
separated by SDS-PAGE (10%) and immunoblotted with anti-Ang1
antibody (PA-hAng1FD-1) and anti-Ang2 antibody. The multimeric di-
sulfide pattern of native Ang1 and mainly dimeric disulfide pattern of
native Ang2 are seen.Numbers and bars indicate molecular sizes (kDa).
C, nonreduced (NR) and reduced (R) recombinant Ang1 and Ang2
proteins were separated by SDS-PAGE (5–15%) and stained with Coo-
massie Blue. The multimeric disulfide pattern of recombinant Ang1 and
dimeric disulfide pattern of recombinant Ang2 are seen. Numbers and
bars indicate molecular sizes (kDa). D, glycerol spraying/low angle
rotary metal-shadowed specimens were imaged by TEM. Ang1 reveals
variably sized multimers with basic “mushroom-shaped” trimeric, tet-
rameric, and pentameric structures, whereas most Ang2 reveals basic
mushroom-shaped trimeric, tetrameric, and pentameric structures
with rare cases of multimeric structures.
FIG. 2. Schematic diagrams of Ang1 and Ang2 variants. In
Ang1/FD, amino acids 20–282 are deleted; in Ang1D1 (D1), Ang2D2
(D2) and AngD3 (D3), amino acids 20–80, 20–118, and 20–152 are
deleted, respectively; in Ang1C265S (A1S), cysteine 265 of Ang1 is
replaced by serine; in Ang1C41S/C54S (A1D), cysteines 41 and 54 are
replaced by serines; in Ang2S263C (A2C), serine 263 of Ang2 is replaced
by cysteine. S, secretory signal sequence; SCD, superclustering domain;
CCOD, coiled-coil oligomeric domain; L, linker; FLD, fibrinogen-like
domain.
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sTie1-Fc. Accordingly, Ang1D1, AngD2, and Ang1D3 did not
phosphorylate Tie2 (Fig. 5D). These results indicate that
proper oligomerization/multimerization of Ang1 by its super-
clustering domain is a prerequisite for Tie2 binding and acti-
vation. In addition, more than a tetrameric form of Ang1 is
required for Tie2 binding and activation.
Cysteines 41 and 54 of Ang1 Are Critical for Its Proper
Oligomerization/Multimerization, Tie2 Binding, and Tie2 Acti-
vation—To define role of cysteines 41 and 54 of Ang1, we
generated a recombinant Ang1 protein with both cysteines
replaced with serine (Ang1C41S/C54S) (Fig. 2). Although SDS-
PAGE analyses revealed that Ang1C41S/C54S formed mainly
dimers with a minor fraction of monomers (Fig. 6A), RMSTEM
analyses revealed that Ang1C41S/C54S formed mainly dimers
and trimers that were similar to Ang1D1 (Fig. 6B). As a con-
trol, Ang1 formed large variable multimers, and Ang1C265S
formed predominantly a single band of molecular mass 120
kDa (Fig. 6A). In vitro binding assays revealed that 5% of the
total protein amount of Ang1C41S/C54S bound to sTie2-Fc
(data not shown). Accordingly, neither concentration of
Ang1C41S/C54S (400 and 1,000 ng/ml) phosphorylated Tie2,
whereas Ang1 and Ang1C265S induced Tie2 phosphorylation,
as expected (Fig. 6C). These results indicate that proper oli-
gomerization/multimerization of Ang1 by its intermolecular
disulfide link involving between cysteine 41 and cysteine 54 is
critical for Tie2 binding and activation. In addition, a trimeric
form of Ang1 is not sufficient for its Tie2 binding and
activation.
DISCUSSION
The angiopoietin family proteins are oligomeric and multi-
meric ligands (1, 14–16, 25, 26). Structure-function studies on
oligomeric and multimeric ligands provide an important clue as
to how they activate their receptors and new directions to
improve their activity by protein engineering. However, it is
generally difficult to generate recombinant oligomeric and mul-
timeric ligands because they are often insoluble and poorly
secreted from host cells (15, 17). Nevertheless, we have been
able to generate several variant proteins of Ang1 and Ang2
successfully through mammalian cell expression systems. Us-
ing SDS-PAGE, RMSTEM, in vitro binding assays, and Tie2
phosphorylation assays, we provide several critical clues about
the structure-function relationship of Ang1 and Ang2. This
information could be applied beyond angiopoietin family pro-
teins to other oligomeric and multimeric ligands such as eph-
rin, thrombopoietin, thrombospondin, angiopoietin-related pro-
teins, and adiponectin.
RMSTEM revealed that the basic structures of Ang1 and
Ang2 recombinant proteins are trimers, tetramers, and pen-
tamers. Ang1 exists as heterogeneous multimers made up of
basic trimeric, tetrameric, or pentameric oligomers, whereas
FIG. 3. The cysteine residue in the linker region is critical for
multimerization of Ang1 and for aggregation of Ang2. A, nonre-
duced Ang1, Ang1C265S, Ang2, and Ang2S263C proteins were sepa-
rated by SDS-PAGE (5–15%) and stained with Coomassie Blue. Num-
bers and bars indicate molecular sizes (kDa). B, glycerol spraying/low
angle rotary metal-shadowed specimens were imaged by TEM.
Ang1C265S reveals mainly trimers, tetramers, and pentamers,
whereas Ang2S263C reveals mainly nonspecific aggregates with rare
cases of trimers, tetramers, and pentamers. C, serum-starved HUVECs
were treated with control buffer (CB), 200 ng/ml Ang1, 200 ng/ml
Ang1C265S (A1S), 200 ng/ml Ang2, or 200 ng/ml Ang2S263C (A2C) for
10 min, and the phosphorylation of Tie2 was measured. Fold, densito-
metric analyses presented as the relative ratio of phospho-Tie2 to Tie2.
The relative ratio of phospho-Tie2 to Tie2 with control buffer is arbi-
trarily presented as 1. Numbers represent the mean  S.D. from four
experiments. *, p  0.05 versus control buffer.
FIG. 4. Monomeric Ang1 does not bind to or phosphorylate
Tie2. A, reduced (R) and nonreduced (NR) Ang1 and Ang1/FD proteins
were separated by SDS-PAGE (5–15%) and immunoblotted with anti-
FLAG antibody. Numbers and bars indicate molecular sizes (kDa). B,
in vitro binding analysis with control buffer (CB), sTie1-Fc (T1), and
sTie2-Fc (T2). Approximately 75 and 0% of the total protein amount of
Ang1 and Ang1/FD, respectively, bound to Tie2. The results from three
experiments were similar. TAP, total amount of protein input for bind-
ing assay. C, serum-starved HUVECs were treated with control buffer
(CB), 200 ng/ml Ang1, and 400 ng/ml Ang1/FD for 10 min, and the
phosphorylation of Tie2 was measured. The results from three experi-
ments were similar.
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Ang2 exists mainly as trimeric, tetrameric, or pentameric oli-
gomers with a few multimers. These results may explain the
fact that recombinant Ang1 protein is less soluble, moderately
sticky, easily aggregated, and unstable for Tie2 activation,
whereas recombinant Ang2 protein is relatively soluble, non-
sticky and nonaggregative. In fact, consistent with a recent
report (27) showing that a brain pericyte cell line (TR-PCT1)
secretes variable multimeric forms of Ang1, our results showed
that the 3T3-L1 cell line also secretes variable multimeric
forms of Ang1. These results suggest that native Ang1 could
consist of variable multimeric forms. In comparison, based on
SDS-PAGE analysis, we and others have shown that recombi-
nant Ang2 is present as disulfide-linked dimers (2, 14, 22). Our
present SDS-PAGE analysis revealed that native Ang2 is pres-
ent mainly as disulfide-linked dimers. However, unexpectedly,
our RMSTEM analysis indicated that recombinant Ang2 was
present as trimers, tetramers, pentamers, with a small fraction
of multimers. Thus, native Ang2 could consist of variable oli-
gomeric forms. Importantly, a recent report (28) indicates that
endogenous and overexpressed endothelial cell Ang2 is present
as a characteristic granular pattern in the Weibel-Palade body
and is secreted within minutes of cell stimulation (e.g. by phor-
bol 12-myristate 13-acetate, thrombin, or histamine). This find-
ing suggests that, in addition to angiogenesis, Ang2 is likely to
be involved in rapid vascular homeostatic reactions, such as
inflammation and coagulation. It is also worthwhile to note
that a very recent report (29) described the role of the coiled-
coil domain of Ang1 (Ang1cc). This can heterodimerize with
other angiopoietins produced in the same cell but is unable to
bind to Tie2 because it lacks the multimerized binding domain.
Thus, Ang1cc can inhibit Tie2 activation and can inhibit Ang1
activity in vitro and in vivo. It is possible that Ang1 molecules
with very high order multimeric structures would not be active
because they may be too big to enter endothelial cell caveolae,
where most Tie2 receptors are located (30). For comparison, the
doorway diameters of endothelial caveolae are typically 10–150
nm (31), whereas the sizes of higher order multimeric Ang1
molecules are more than 200 nm. Thus, high order multimeric
Ang1 could not access most of Tie2 as well as bind and activate
it. In the future, detailed ultrastructural analysis on the inter-
action between oligomeric/multimeric Ang1 and Tie2 in caveo-
lae would be helpful in understanding why recombinant Ang1
is not always active.
FIG. 5. The superclustering domain of Ang1 is critical for
higher order oligomerization and Tie2 binding and activation.
A, reduced (R) and nonreduced (NR) deletion variants of Ang1 proteins
are separated by SDS-PAGE (5–15%) and stained with Coomassie Blue.
Numbers and bars indicate molecular sizes (kDa). B, glycerol spraying/
low angle rotary metal-shadowed specimens were imaged by TEM.
Ang1D1 reveals mainly dimeric and trimeric structures, whereas
Ang2D2 and AngD3 reveal dimeric structures. C, in vitro binding anal-
ysis with control buffer (CB), sTie1-Fc (T1), and sTie2-Fc (T2). Approx-
imately 72, 12, 4, and 6% of the total protein amount of Ang1, Ang1D1,
Ang2D2, and AngD3, respectively, bound to Tie2. The results from
three experiments were similar. TAP, total amount of protein input for
binding assay. D, serum-starved HUVECs were treated with control
buffer (CB), 200 ng/ml Ang1 (A1), 400 ng/ml Ang1D1 (D1), 400 ng/ml
Ang1D2 (D2), or 400 ng/ml Ang1D3 (D3) for 10 min, and the phospho-
rylation of Tie2 was measured. Fold, densitometric analyses presented
as the relative ratio of phospho-Tie2 (pTie2) to Tie2. The relative ratio
of phospho-Tie2 to Tie2 with control buffer is arbitrarily presented as 1.
Numbers represent the mean  S.D. from four experiments. *, p  0.05
versus control buffer.
FIG. 6. Cysteines residues 41 and 54 of Ang1 are critical for
higher order oligomerization, and Tie2 binding and activation.
A, nonreduced Ang1, Ang1C41S/C54S, and Ang1C265S proteins were
separated by SDS-PAGE (5–15%) and stained with Coomassie Blue.
Numbers and bars indicate molecular sizes (kDa). M, molecular
marker. B, glycerol spraying/low angle rotary metal-shadowed speci-
mens were imaged by TEM. Ang1C41S/C54S reveals mainly dimeric
and trimeric structures. C, serum-starved HUVECs were treated with
control buffer (CB), 200 ng/ml Ang1, 200 ng/ml Ang1C265S (A1S), or
Ang1C41S/C54S (A1DL, 400 ng/ml; A1DH, 1,000 ng/ml) for 10 min, and
the phosphorylation of Tie2 was measured. Fold, densitometric analy-
ses presented as the relative ratio of phospho-Tie2 (pTie2) to Tie2. The
relative ratio of phospho-Tie2 to Tie2 with control buffer is arbitrarily
presented as 1. Numbers represent the mean  S.D. from four experi-
ments. *, p  0.05 versus control buffer.
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Our present data indicate that a tetrameric form of Ang1 is
the minimal unit size required to activate Tie2. Notably, di-
meric and trimeric Ang1D3 and Ang1C41S/C54S variant pro-
teins completely lost their ability to bind and activate Tie2,
whereas trimeric, tetrameric, and pentameric Ang1C265S
yields less Tie2 activation than does Ang1, indicating that only
the tetrameric or pentameric form of Ang1 has the ability to
bind and activate Tie2. Although trimeric Ang1C265S is not
able to induce Tie2 binding and activation, tetrameric and
pentameric Ang1C265S and higher order oligomeric
Ang1C265S made by an intermolecular disulfide linkage be-
tween cysteine 41 and cysteine 54 are able to induce Tie2
binding and activation. Consistent with a recent report (15),
monomeric Ang1/FD did not bind or activate Tie2. Even di-
meric Ang1D2 and Ang1D3 variant proteins dramatically lost
their ability to bind and activate Tie2. These results are con-
sistent to our previous report (16) that our designed dimeric
Ang1, GCN4-Ang1, does not have the properties needed to bind
and activate Tie2. In comparison, designed Ang1 variants
MAT-Ang1, which forms mainly tetramers, and COMP-Ang1,
which forms tetramers and pentamers, are able to bind and
activate Tie2 (16). Thus, oligomers of Ang1 having at least four
subunits are required for binding and activation of Tie2. This is
also consistent with the work of Davis et al. (15). Detailed
stoichiometric and structural analysis is necessary to under-
stand why oligomerization of more than three subunits of Ang1
is required for these activities. To define the role of the two
cysteines (amino acids 41 and 54) in the superclustering do-
main of Ang1, we generated Ang1C41S/C54S. In fact,
Ang1C41S/C54S formed mostly dimers and trimers, and it was
not able to bind and activate Tie2. Thus, the two cysteines
(amino acids 41 and 54) in the superclustering domain of Ang1
are responsible for the formation of higher order oligomers/
multimers by cross-linking Ang1 dimers and trimers, whereas
the coiled-coil domain is responsible for dimer and trimer for-
mation of Ang1. Thus, proper oligomerization of Ang1 by the
disulfide link between cysteine 41 and cysteine 54 is critical for
Tie2 binding and activation. It is worthwhile to note that a
recent report (32) described the role of the two cysteines (amino
acids 76 and 80) in the superclustering domain of an angiopoi-
etin-like protein (also known as Angptl4, HFARP, PGAR,
FIAF). As in Ang1C41S/C54S, replacing these two cysteines
with alanines in Angptl4 abolished its oligomerization. Addi-
tion of cysteine in the linker region of Ang2 (Ang2S263C)
dramatically induced nonspecific Ang2 aggregation rather
than well arranged high order multimerization. Evidently,
nonspecific Ang2 aggregates per se have no effect on Tie2
activation.
In conclusion, our data clarified on the structure-function
relationships of Ang1 and Ang2 with Tie2. The basic structures
of native and recombinant Ang1 and Ang2 proteins could be
trimers, tetramers, and pentamers formed through the coiled-
coil oligomerization domain. Two cysteines (residues 41 and 54)
in the superclustering domain of Ang1 are responsible for
higher order oligomer formation by cross-linking of Ang1 trim-
ers, tetramers, and pentamers. Thus, proper oligomerization of
Ang1 by the disulfide link between cysteine 41 and cysteine 54
is critical for Tie2 binding and activation.
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